Emerald Mutual Fund Advisers Trust Sells 17,205 Shares of TransMedics Group, Inc. $TMDX

Emerald Mutual Fund Advisers Trust decreased its position in TransMedics Group, Inc. (NASDAQ:TMDX) by 6.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 238,438 shares of the company’s stock after selling 17,205 shares during the period. TransMedics Group comprises approximately 1.4% of Emerald Mutual Fund Advisers Trust’s holdings, making the stock its 17th largest holding. Emerald Mutual Fund Advisers Trust owned 0.70% of TransMedics Group worth $26,753,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of TMDX. Geode Capital Management LLC increased its position in shares of TransMedics Group by 1.4% during the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock valued at $107,845,000 after purchasing an additional 11,241 shares during the period. Marshall Wace LLP boosted its stake in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after buying an additional 394,340 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares in the last quarter. Zevenbergen Capital Investments LLC increased its holdings in TransMedics Group by 112.7% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company’s stock valued at $29,006,000 after buying an additional 136,995 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in TransMedics Group by 5.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 221,276 shares of the company’s stock valued at $29,653,000 after buying an additional 11,599 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Insiders Place Their Bets

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the transaction, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Gerardo Hernandez sold 920 shares of the stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the sale, the chief financial officer owned 15,064 shares in the company, valued at $2,103,235.68. The trade was a 5.76% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a report on Sunday, December 28th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Jefferies Financial Group began coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 price objective on the stock. Piper Sandler reissued an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $138.09 on Friday. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The firm has a market cap of $4.72 billion, a PE ratio of 55.91 and a beta of 2.03. TransMedics Group, Inc. has a 12 month low of $58.54 and a 12 month high of $156.00. The company’s 50-day moving average price is $132.43 and its two-hundred day moving average price is $122.93.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. The company had revenue of $143.82 million during the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. TransMedics Group’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 earnings per share. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.